Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPV23 Revaccination in Elderly
NCT04701788Phase 4Completed
- Sponsor
- China National Biotec Group
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by China National Biotec Group. Started Mar 2021; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04701788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701788.